Fundz

Fundz Deep Dive

Everything you need to win Vivani — in one platform.

Who to reach, what to say, and why now on Vivani — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Vivani — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Vivani Medical announces $8.25M private placement equity financing

Mar 27, 2025•about 1 year ago

Contract Type

partnership

AlamedaBiotechnologyHealth CarePharmaceuticalBiopharma

Description

Vivani Medical, Inc. announced a securities purchase agreement to issue and sell an aggregate of 7,366,071 shares at a price of $1.12 per share, resulting in gross proceeds of approximately $8.25 million in a private placement. The financing is aimed at extending the company's expected cash runway into the second quarter of 2026 and enabling accelerated development of NPM-139, the company’s GLP-1 (semaglutide) implant for chronic weight management.

Company Information

Company

Vivani

Location

Alameda, California, United States

About

Vivani Medical is a pre-clinical-stage developer of long-term pharmaceutical implants aimed at revolutionizing the treatment of patients with chronic diseases. Leveraging its proprietary NanoPortal™ platform, Vivani’s portfolio of tiny, sub-dermal drug implants address medication non-adherence by providing steady levels of medication over a target duration of six months or longer. Vivani is developing two miniature, long-term GLP-1 implants for the treatment of obesity and chronic weight management: NPM-115 (exenatide) and NPM-139 (semaglutide). In addition, the company is developing NPM-119, a lower dose exenatide implant for the treatment of type 2 diabetes.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Vivani's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.